Evidence map›Paper›PMID 31593551›Full record

ArticleBiomedical materials (Bristol, England)2019

Optimization of polycaprolactone fibrous scaffold for heart valve tissue engineering.

Soumen Jana, Amrita Bhagia, Amir Lerman

Open access · greenAbstract read
In one paragraph

Article in Biomedical materials (Bristol, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Regenerative medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Soumen JanaDepartment of Bioengineering, University of Missouri, Columbia, MO 65211, United States of America.ORCID 0000-0001-7191-6700
Amrita BhagiaDivision of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States of America.
Amir LermanDivision of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States of America.
Mayo Clinic · US

Funding

Nanotechnology in tissue engineering for autologous cardiac valve developmentR00HL134823 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI JANA, SOUMEN · 2019 to 2021
$745k
Nanotechnology in tissue engineering for autologous cardiac valve developmentK99HL134823 · NHLBI · MAYO CLINIC ROCHESTER · PI JANA, SOUMEN · 2017 to 2018
$256k
NHLBI NIH HHS K99 HL134823NHLBI NIH HHS R00 HL134823
6 · The paper itself

Abstract

Pore size is generally small in nanofibrous scaffolds prepared by electrospinning polymeric solutions. Increase of scaffold thickness leads to decrease in pore size, causing impediment to cell infiltration into the scaffolds during tissue engineering. In contrast, comparatively larger pore size can be realized in microfibrous scaffolds prepared from polymeric solutions at higher concentrations. Further, microfibrous scaffolds are conducive to infiltration of reparative M2 phenotype macrophages during in vivo/in situ tissue engineering. However, rise of mechanical properties of a fibrous scaffold with the increase of polymer concentration may limit the functionality of a scaffold-based, tissue-engineered heart valve. In this study, we developed microfibrous scaffolds from 14%, 16% and 18% (wt/v) polycaprolactone (PCL) polymer solutions prepared with chloroform solvent. Porcine valvular interstitial cells were cultured in the scaffolds for 14 d to investigate the effect of microfibers prepared with different PCL concentrations on the seeded cells. Further, fresh microfibrous scaffolds were implanted subcutaneously in a rat model for two months to investigate the effect of microfibers on infiltrated cells. Cell proliferation, and its morphologies, gene expression and deposition of different extracellular matrix proteins in the in vitro study were characterized. During the in vivo study, we characterized cell infiltration, and myofibroblast and M1/M2 phenotypes expression of the infiltrated cells. Among different PCL concentrations, microfibrous scaffolds from 14% solution were suitable for heart valve tissue engineering for their sufficient pore size and low but adequate tensile properties, which promoted cell adhesion to and proliferation in the scaffolds, and effective gene expression and extracellular matrix deposition by the cells in vitro. They also encouraged the cells in vivo for their infiltration and effective gene expression, including M2 phenotype expression.

Indexed as

AnimalsAortic ValveAortic Valve StenosisCalcinosisCell AdhesionCell ProliferationCells, CulturedCollagenElastinExtracellular MatrixGlycosaminoglycansMesenchymal Stem CellsNanofibersPolyestersPolymersRatsCollagenElastinGlycosaminoglycanspolycaprolactonePolyestersPolymersVimentin

Identifiers

PMID31593551
PMCPMC7402270
OpenAlexW2980137351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.